Human pluripotent stem cell-derived cardiomyocytes: Genome-wide expression profiling of long-term in vitro maturation in comparison to human heart tissue  by Piccini, Ilaria et al.
Genomics Data 4 (2015) 69–72
Contents lists available at ScienceDirect
Genomics Data
j ou rna l homepage: ht tp : / /www. journa ls .e lsev ie r .com/genomics-data /Data in BriefHuman pluripotent stem cell-derived cardiomyocytes: Genome-wide
expression proﬁling of long-term in vitro maturation in comparison to
human heart tissueIlaria Piccini a,1, Jyoti Rao b,c,1, Guiscard Seebohm a, Boris Greber b,c,⁎
a Institute of Genetics of Heart Diseases (IfGH), Deptartment of Cardiovascular Medicine, University Hospital Münster, Münster, Germany
b Human Stem Cell Pluripotency Laboratory, Max Planck Institute for Molecular Biomedicine, Münster, Germany
c Chemical Genomics Centre of the Max Planck Society, Dortmund, Germany⁎ Corresponding author at: Max Planck Institute for
Esmarch-Straße 54, D-48149 Münster, Germany. Tel.: +4
E-mail address: boris.greber@mpi-muenster.mpg.de (
1 These authors contributed equally to the present man
http://dx.doi.org/10.1016/j.gdata.2015.03.008
2213-5960/© 2015 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 18 March 2015
Accepted 24 March 2015
Available online 1 April 2015
Keywords:




Human heartCardiomyocyte-like cells (CMs) derived from human pluripotent stem cells (hPSCs) present a valuablemodel for
human disease modeling, studying early human development and, potentially, developing cell therapeutic ap-
proaches. However, the speciﬁcation of early hPSC-derived CMs into deﬁned cardiac subtypes such as atrial
and ventricular cells is not well understood and, thus, poorly controlled. Moreover, the maturation status of
hPSC-CMs is not well deﬁned, yet it is known that these cells undergo at least some degree of maturation
upon longer term in vitro culture. To gain insight into this process, and to assess their developmental status,
we have recently generated a data set of hPSC-CMs monitoring global changes in gene expression upon long
termmaintenance in vitro, in comparison to human atrial and ventricular heart samples (GEO accession number
GEO: GSE64189). These data present a rich resource for evaluating the maturation status of hPSC-CMs, for iden-
tifying suitable markers for subtype-speciﬁc gene expression, as well as for the generation of functional hypoth-
eses. Here, we provide additional details and quality checks of this data set, and exemplify how it can be used to
identify maturation-associated as well as cardiac subtype-speciﬁc markers.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).SpeciﬁcationsOrganism/cell line/tissue Homo sapiens/hPSC line FS3F.2/Atrial and ventricular
heart biopsiesSex Male
Sequencer or array type HumanHT-12 v4
Data format Raw and processed
Experimental factors hPSC-derived CMs: untreated cells harvested at weekly
intervals
Experimental features hPSCs were differentiated into cardiomyocytes and
maintained under adherent culture conditions in low
fetal calf serum-containing media. Samples were taken at
weekly intervals up to 8 weeks. Human atrial and ven-
tricular biopsy samples served as in vivo reference.Consent Written informed consent was obtained from patients
where applicable.Sample source location Münster, GermanyMolecular Biomedicine, Von-
9 251 83 46906.
B. Greber).
uscript.
. This is an open access article underDirect link to deposited data
Deposited data can be foundhere: http://www.dtd.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE64189.
Experimental Design, Materials and Methods
Generation and processing of samples
Cell culture. hPSCs, cell line FS3F.2 [1], were maintained in FTDA
medium [2], on Matrigel™-coated dishes. Cardiac differentiation was
induced as described [3]. In brief, fully conﬂuent hPSC cultures were
harvested using Accutase™ digestion, and replated onto Matrigel-
coated 24-well plates (500,000 cells per well in 2 ml of day 0 differ-
entiation medium). An aliquot of cells was used for RNA isolation
(0 week time-point). Day 0 differentiation medium contained
Knockout™ DMEM, insulin/transferrin/selenium, 10 μM Y27632,
penicillin/streptomycin/L-Glutamine, 10 ng/ml FGF2, 1 ng/ml BMP4,
and 1 μM CHIR99021 [3]. Day 1 medium contained Knockout™ DMEM
transferrin/selenium penicillin/streptomycin/L-Glutamine, and 250 μM
phospho-ascorbate (TS medium). On days 2 and 3, cells were fed withthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Biological quality assessment. (A) Scatter plot analysis (power scale) of early hPSC-CMs versus undifferentiated hPSCs (left), late vs. early hPSC-CMs (middle), and 8 week vs.
4 week-old hPSC-CMs (right). Linear correlation coefﬁcients are provided as a measure for global transcriptome similarity. Blue colored dots indicate data points of known marker
genes. See text for discussion. (B) ACTC1 as a pan-cardiac marker is expressed at similar levels in all differentiated in vitro samples (from 1 week onwards). Error bars indicate bead stan-
dard deviation extracted from GenomeStudio.
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after, cells were maintained in basal TS medium. Spontaneous beating
was observed from day 6 onwards. CM differentiation efﬁciency was
above 85% as judged by FACS counting [3]. On day 7, the cells were har-
vested using 1× TrypLE Select (Life Technologies), and pooled from in-
dependent samples. An aliquot of cells was used for RNA isolation
(1 week time-point), and the remaining cells replated at ~250,000
cells per well of a Matrigel-coated 24-well plate, in 2% fetal calf serum/
Knockout DMEM/penicillin/streptomycin/L-Glutamine. Thereafter, me-
dium was replaced every 3–4 days. Samples of maturating hPSC-CMs
were taken at weekly intervals up to 8 weeks, to be subjected to micro-
array analysis. Total RNA was isolated using Qiagen RNeasy columns
with on-column DNA digestion.
Human heart samples. RNA samples from left and right atrial ap-
pendages have been previously described [4]. RNA sampleswere pooled
from six independent patients per tissue type. The human left and right
ventricular RNA samples were from a commercial supplier (Biocat
#R1234138‐50‐BC and #R1234139‐50‐BC, respectively).
500 ng of total RNA from each biological samplewas used as input for
the generation of biotin-labeled cRNA using an Illumina® TotalPrep™
RNA ampliﬁcation kit (Life Technologies). Following the manufacturer's
instructions, in vitro transcription of double-stranded cDNA was per-
formed for 14 h, in a PCR cycler. Puriﬁed biotin-labeled cRNAwas eluted
in a volume of 100 μl and quality-checked on a 2100 Bioanalyzer device
(Agilent Technologies). cRNA samples were adjusted to 150 ng/μl in
water, and hybridized onto Illumina HumanHT-12 v4 bead arrays
following the manufacturer's instructions throughout. Hybridization
was carried out at 58 °C for 18 h. Staining with streptavidin-Cy3 (GE
Healthcare #PA43001)was carried out as recommended, at a concentra-
tion 1 μg/ml in blocking buffer. Dried bead arrays were scanned on a
HiScan SQ device (Illumina) using default settings.Fig. 2. Comparison of adult human atrial and ventricular tissue (scatter plot of combined
left/right samples). Selected marker genes are highlighted by colored dots. Note that
MYL7 (MLC2a) is also highly expressed in ventricular tissue.Technical and biological data quality assessment
Scanned images were conﬁrmed to show an overall clean ﬂuores-
cence spot morphology with high signal-to-noise ratio, and array data
were conﬁrmed to display an average P95 intensity of N800 (a.u.). In-
spection of rawdata in GenomeStudio suggested anoverall high hybrid-
ization stringency, according to internal mismatch control probes, and
nomajor hybridization artifacts. Following these routine checks, all sep-
arately hybridized samples were background-subtracted and normal-
ized using the Cubic Spline algorithm in GenomeStudio. This revealed
a high degree of similarity between the left/right human heart samples,
suggesting that they could be combined in silico. To assess overall
human heart-speciﬁc gene expression regardless of chamber-speciﬁcdifferences, data was additionally analyzed by combining all human
atrial and ventricular samples using GenomeStudio software.
As a biological quality control step, knownmarkers were used to as-
sess differential gene expression between the distinct types of samples.
In line with the expectations, hPSC-speciﬁc genes OCT4, NANOG and
SOX2were only expressed in the undifferentiated (0 week) cells. Con-
versely, structural cardiac markers (MYH6, MYL4, MYL7) were indeed
only expressed in the differentiated samples and not in the undifferen-
tiated cells (Fig. 1A, left). Focusing on gene expression changes upon
long-term in vitro culture, maturation markers such as MYL2 and
MYH7 were upregulated in the late (8 weeks) samples, whereas
markers of immature hPSC-CMs were indeed overrepresented in the
early (1week) samples (Fig. 1A,middle). As supported by functional as-
says [3], however, there were only marginal differences between
4 weeks and 8 week-old hPSC-CMs, suggesting that the cells reach a
rather stable transcriptomic state from approximately 4weeks onwards
(Fig. 1A, right). Furthermore, the expression pattern of the pan-cardiac
marker ACTC1 (cardiacmuscle alpha actin) served to indicate an overall
stable cardiomyocyte signature in all differentiated samples (1 to
8 weeks, Fig. 1B).
Table 1
Marker genes discriminating between human atrial and ventricular tissue and corresponding expression levels in late (4–8weeks) hPSC-CMs. P values for differential gene expression are
below 0.01 in all cases.
Symbol Atria signal Ventricles signal Fold change (V/A or A/V) hPSC-CMs 4–8 weeks signal Deﬁnition
Human ventricular markers
DLK1 5 341 68 924 Delta-like 1 homologue (Drosophila)
IRX4 5 204 41 252 Iroquois homeobox 4
MYL2 444 18,009 41 6769 Myosin, light polypeptide 2, regulatory, cardiac, slow
XDH 5 188 38 33 Xanthine dehydrogenase
TMEM190 7 255 37 46 Transmembrane protein 190
HYAL2 16 532 34 112 Hyaluronoglucosaminidase 2
CPNE4 20 650 32 Below detection Copine IV
CYP1A1 5 158 32 Below detection cytochrome P450, family 1, subfamily A, Polypeptide 1
IRX5 14 387 27 42 Iroquois homeobox protein 5
C3orf23 5 112 22 24 Chromosome 3 open reading frame 23
Human atrial markers
NPPB 15,780 19 824 2043 Natriuretic peptide precursor B
HAMP 1548 5 310 29 Hepcidin antimicrobial peptide
MYBPHL 922 5 184 Below detection Myosin binding protein H-like
NPPA 21,892 143 153 1615 Natriuretic peptide precursor A
PLA2G2A 478 5 101 Below detection Phospholipase A2, group IIA (platelets, synovial ﬂuid)
COMP 396 5 79 Below detection Cartilage oligomeric matrix protein
TCEAL2 761 12 63 19 Transcription elongation factor A (SII)-like 2
SLPI 274 5 55 Below detection Secretory leukocyte peptidase inhibitor
DHRS9 1441 28 52 2251 Dehydrogenase/reductase (SDR family) member 9
HP 1316 27 49 Below detection Haptoglobin
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A comparison of human atrial and ventricular samples allowed for
the identiﬁcation of marker genes. Using stringent ﬁltering criteria
(N10-fold differences in gene expression), these included known
structural genes, ion channels, as well as transcriptional regulators
(Fig. 2, Table 1). For instance, myosin light chain 2 (MYL2, also
known as MLC2v) presents a rather stringent ventricular marker.
By contrast, the frequently used MYL7 (MLC2a) was only about 2-
fold enriched in atrial tissue, suggesting that it does not well dis-
criminate between human cardiac subtypes. Instead, the natriuretic
peptide-encoding genes NPPA and NPPB are excellent atrial markers
according to this analysis.
Analyzing the hPSC-based together with the in vivo data allows de-
termination of shared and divergent gene expression between hPSC-
CMs and human heart. In line with the expectations, scatter plot and
clustering analyses between human heart versus (i) undifferentiated
hPSCs, (ii) early (1 week) hPSC-CMs, and (iii) maturated hPSC-CMs
(combined 4–8 weeks samples) suggest that over time, hPSC-CMs
tend to become more similar to the human adult heart reference
(Fig. 3). This tendency is also supported by the fact that a set of
known immature CM markers (NKX2.5, IRX4, and others) declinesFig. 3. Comparison of hPSC-CMs and human heart tissue. (A) Global correlation-based dendrog
closer to human heart (combined atrial and ventricular samples) than to undifferentiated hPSCs
types of samples are highlighted by different colors (black: hPSCs, blue: early hPSC-CMs, orangupon long-term in vitro culture, whereas a set of maturation marker
genes (MYH7, MYL2, and others) reached human heart-like expression
levels over time (blue and orange colored genes, respectively, in Fig. 3).
However, even in late hPSC-CMs a number of human heart genes were
not expressed, and the global similarity to the in vivo reference appears
to be rather limited (red colored genes in Fig. 3, Table 2).Discussion
Despite the fact that neither the in vitro-derived nor the in vivo
samples consisted of pure populations of cardiomyocytes, this data set
suggests that meaningful biological information can be extracted from
it. The combined hPSC-CM/adult human heart data hence presents a
useful resource for evaluating the maturation status of hPSC-CMs
at the transcriptional level as well as for assessing cardiac
subtype-speciﬁc gene expression. Notably, according to our analy-
sis, the frequently usedMYL7 (MLC2a) gene appears to be unsuited
for discriminating between atrial and ventricular subtypes. Our
data instead suggests alternative genes, such as NPPA and NPPB, as
being well-suited markers for evaluating atrial subtype speciﬁca-
tion in hPSC-CMs.ram showing early (1 week-old) and late (combined 4–8 weeks-old) hPSC-CMs clustering
. (B) Scatter plots comparing the indicated samples. Examples of genes enriched in the four
e: late hPSC-CMs and human heart, red: human heart).
Table 2
Selected genes enriched in early hPSC-CMs, late hPSC-CMs, and human heart. P values for differential gene expression are below 0.01 in all cases.
Symbol hPSCs 0 week signal hPSC-CMs 1 week signal hPSC-CMs 4–8 weeks
signal
Human heart atr. & ventr. signal Deﬁnition
Genes upregulated in early hPSC-CMs
NKX2-5 Below detection 3201 1549 583 NK2 transcription factor related, locus 5
IRX4 67 1036 276 132 Iroquois homeobox 4
TBX2 Below detection 1536 331 152 T-box 2
COL2A1 20 694 39 Below detection Collagen, type II, alpha 1
ISL1 23 269 17 Below detection ISL1 transcription factor, LIM/homeodomain
HAND1 Below detection 4480 1231 632 heart and neural crest derivatives expressed 1
ID2 110 1339 83 228 Inhibitor of DNA binding 2
LEF1 15 501 47 Below detection Lymphoid enhancer-binding factor 1
IRS1 53 546 241 117 Insulin receptor substrate 1
MDK 23 532 201 Below detection Midkine (neurite growth-promoting factor 2)
Genes upregulated in late hPSC-CMs and human heart
MYH7 Below detection 938 11,781 13101 Myosin, heavy chain 7, cardiac muscle, beta
MYL2 Below detection 41 6838 7737 Myosin, light polypeptide 2, regulatory, cardiac, slow
TNNI3K below detection 46 757 659 TNNI3 interacting kinase, transcript variant 2
HSPB7 Below detection 3339 5428 5614 Heat shock 27 kDa protein family, member 7
PLN Below detection 1534 4645 4638 Phospholamban
CSRP3 below detection 540 1297 2317 Cysteine and glycine-rich protein 3
ACTN2 Below detection 813 1130 1739 Actinin, alpha 2
RBM20 below detection 440 1121 1426 RNA binding motif protein 20
TRIM63 Below detection 367 1116 1544 Tripartite motif-containing 63
CORIN Below detection 444 934 976 Corin, serine peptidase
Genes upregulated in human heart
CASQ2 Below detection 10 23 6699 Calsequestrin 2 (cardiac muscle)
MB Below detection 727 633 12450 Myoglobin, transcript variant 1
MYOM2 14 41 180 8272 Myomesin (M-protein) 2
TCAP Below detection 264 922 8830 Titin-cap (telethonin)
MYH11 below detection 147 201 1835 Myosin, heavy chain 11
TNNI3 34 331 401 9157 Troponin I type 3 (cardiac)
S100A1 Below detection 10 10 1482 S100 calcium binding protein A1
DES Below detection 14 56 4555 Desmin
HRC 24 1294 1105 4976 Histidine rich calcium binding protein
MYOM1 Below detection 4787 4668 10215 Myomesin 1, transcript variant
72 I. Piccini et al. / Genomics Data 4 (2015) 69–72Acknowledgments
This work was supported by the Chemical Genomic Centre of the
Max Planck Society.
References
[1] B. Greber, et al., FGF signalling inhibits neural induction in human embryonic stem
cells. EMBO J. 30 (24) (2011) 4874–4884.[2] S. Frank, M. Zhang, H.R. Scholer, B. Greber, Small molecule-assisted, line-independent
maintenance of human pluripotent stem cells in deﬁned conditions. PLoS One 7 (7)
(2012) e41958.
[3] M. Zhang, et al., Universal cardiac induction of human pluripotent stem cells in 2D
and 3D formats — implications for in-vitro maturation. Stem Cells (2015) http://dx.
doi.org/10.1002/stem.1964.
[4] P.C. Kahr, et al., Systematic analysis of gene expression differences between left and
right atria in different mouse strains and in human atrial tissue. PLoS One 6 (10)
(2011) e26389.
